What are the differences between Pediatric Acute‑onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

PANS vs PANDAS: Key Differences

PANDAS is a subset of PANS—the critical distinction is that PANDAS requires temporal association with Group A Streptococcal infection, while PANS is a broader clinical syndrome that can be triggered by various infections or remain idiopathic.

Defining Characteristics

PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections)

  • Requires documented temporal relationship between Group A β-hemolytic Streptococcus (GAS) infection and symptom onset/exacerbation 1, 2
  • More narrowly defined construct with specific infectious trigger 2
  • Characterized by 10-fold higher anti-streptolysin O (ASO) and anti-DNAse B titers compared to PANS 3
  • Initially described by Swedo and colleagues in 1998 1

PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome)

  • Broader clinical syndrome not requiring streptococcal association 2
  • Can be triggered by multiple infectious agents including Mycoplasma pneumoniae, influenza, Borrelia burgdorferi, Epstein-Barr virus, SARS-CoV-2, or remain idiopathic 2
  • Defined by rapid onset of obsessive-compulsive symptoms OR severe food restriction, plus concurrent neuropsychiatric features 2
  • More frequently presents with irritability, aggressivity, and food restriction compared to PANDAS (statistically significant, P = 0.024 and P = 0.0023) 3

Clinical Presentation Overlap

Both conditions share substantial clinical features:

  • Abrupt onset of obsessive-compulsive disorder (OCD) or tics 1, 3
  • Neurological symptoms present in >70% of both populations with no significant difference (P = 0.52) 3
  • Psychiatric symptoms similarly prevalent (P = 0.15) 3
  • Mean age at onset approximately 6-8 years 3, 4
  • Multiple concurrent neuropsychiatric symptoms (95% exhibit ≥2 symptoms) 4

Diagnostic Challenges and Pitfalls

Critical caveat: Only 22% of reported PANS/PANDAS cases demonstrate truly sudden symptom onset 4, and core diagnostic criteria (OCD, tics, or acute food refusal) were absent in 12% of labeled cases [@10@]. This highlights significant diagnostic uncertainty in clinical practice.

Common Diagnostic Errors to Avoid:

  • Infection was associated with symptom onset in less than one-third of cases in Canadian surveillance data 4
  • Prospective studies have not uniformly demonstrated consistent temporal relationships between streptococcal infection and neuropsychiatric exacerbations 2
  • Significant diagnostic disagreement exists between physicians and families regarding certainty of diagnosis (P < 0.05) 4
  • No universally accepted diagnostic biomarker currently exists 1, 2

Differential Diagnosis Framework

The 2025 Sydenham chorea consensus guidelines 5 emphasize exploring the relationship between neuropsychiatric symptoms in Sydenham chorea and PANS/PANDAS concepts, as these conditions share autoimmune post-streptococcal mechanisms. PANS/PANDAS must be distinguished from:

  • Autoimmune encephalitis (anti-NMDAR, anti-GABAAR, anti-D2R)
  • Tic disorders and Tourette syndrome
  • Primary psychiatric disorders
  • Sydenham chorea
  • Functional neurological disorders
  • Other post-infectious movement disorders 5

Epidemiology

PANS/PANDAS is rare, with Canadian prevalence estimated at 1 in 60,155 (0.0017%) 4. However, these diagnoses create significant health care utilization and symptom burden when applied 4.

Pathophysiologic Mechanisms (Proposed)

Both conditions share proposed immune mechanisms including:

  • Molecular mimicry with antineuronal antibodies (anti-D1R, anti-D2R)
  • Blood-brain barrier disruption
  • Basal ganglia and cortico-striatal-thalamo-cortical (CSTC) circuit dysfunction
  • Th17 and cytokine-mediated neuroinflammation
  • Gut-oral-brain axis immune interactions 1, 2, 6

None of these mechanisms provides definitive diagnostic confirmation 1, 2.

Clinical Management Implications

The distinction matters for treatment approach:

  • PANDAS cases may warrant antibiotic prophylaxis for documented streptococcal triggers 3
  • Both conditions benefit from psychotherapy, which significantly reduces OCD symptoms (P = 0.042) 3
  • Immunomodulatory therapies remain controversial without validated biomarkers 1, 2
  • Multidisciplinary care with rigorous differential diagnosis is essential 2, 7

The key clinical decision point: Document whether temporal association with GAS infection exists through elevated ASO/anti-DNAse B titers and clinical timeline—this determines PANDAS vs PANS classification and guides antibiotic considerations.

References

Related Questions

What are Pediatric Acute‑onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS)?
In children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), does every streptococcal infection trigger a flare?
What is the recommended treatment for pediatric patients with PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections)?
How should PANS/PANDAS be evaluated and managed in a 10-year-old female with worsening obsessive‑compulsive symptoms?
What is the efficacy of nicotine patch therapy for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS) / Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)?
What is the normal pH range for venous blood?
What is the appropriate management of constipation in an infant younger than 6 months?
What laboratory tests are available to diagnose mast cell activation syndrome?
What is the recommended dosing and safety information for Betahistine dehydrochloride 8 mg tablets for vertigo due to Ménière’s disease?
Can a patient allergic to tetracycline and erythromycin safely receive metronidazole (Flagyl) and ciprofloxacin (Cipro)?
What do dietary changes and salt restriction entail in the management of Ménière’s disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.